推官网,引流量

直推官网引流,大量子站导流 效果持久显著

批量建站,提收录

形成站群推广模式 让搜索引擎大量收录!

提权重,树权威

实现权重提升 树立行业权威

部署快,自主可控

免费下载

省成本,提效率

多分站齐推广,性价比高 批量数据分析,帮助及时调整优化

关于OD
关于OD
特朗普访华,施展欧盟很愚蠢! 特朗普访华很得胜,但目下欧盟又尬在那了,因为他们还
关于OD
中新经纬5月18日电(董湘依)跟着好意思元体系里面实体经济的失衡,东说念主民币外
关于OD
开元棋牌官方网站入口 直播吧5月15日讯中超第12轮,北京国安主场4-2驯顺青岛
日前,国乒队员牛冠凯在酬酢平台告示喜信,晒出共创视频,与竹马之交的退役畅通员段冬
全球知谈,手机圈这两年的竞争还是到了尖锐化的进度,各家子品牌和性能线齐在拚命堆电
凡是稍稍可爱外出游玩的东说念主,齐不得不感喟我们国度的气候有多耐看。从东北漫天飞

OD资讯

ODZIXUN

OD资讯

查看更多
  • OD体育

    OD体育

  • 关于OD

    关于OD

  • OD资讯

    OD资讯

  • OD盘口

    OD盘口

OD盘口

  • OD盘口

OD体育(ODSports)官网入口

  • 302026-04

    OD体育app 危地马拉一餐厅发生枪击致6死2伤:两名枪手闯

    ▲新京报咱们视频出品(ID:wevideo) 4月20日,危地马拉一家餐厅发生持枪紧迫事件,酿成6东谈主物化、2东谈主受伤。 当日,两名持枪须眉闯入餐厅并向主顾开枪,现场专家受惊潜逃,或寻找桌椅作掩体...
  • 162026-05

    OD体育app 18头灰鲸猝死是未必?脂肪隐没、饿死搁浅,罪

    本文着手于海浪天地(Marine Biodiversity) 迎接微信搜索“海浪天地”,怜惜群众环境惩办一手资讯! 本文着手于海浪天地(Marine Biodiversity) 迎接微信搜索“海浪天地...
  • 172026-05

    OD体育app官网 618“值得捡漏”的旗舰手机, 2K屏+

    尽然买手机照旧得恭候618,技术来到5月中旬后,不少主流电商平台上,如故开启618当作了,从15号运转,不少一又友亦然下单出手了我方满意的手机了吧,前两个月加价过的手机,或者一些新机,当今价钱如故运转...
  • 012026-05

    OD体育app官网 孙捷 《乘物游心》2026年度学术特展

    前 言 天地有大好意思而不言,翰墨载至情以抒情。不雅古今艺事之妙,无外乎乘物以游心,托意于翰墨。物者,山川风月、四时万象,为艺之根基;心者,性灵情想、胸臆丘壑,为艺之魂灵。以目接物,以心感物,以笔状物...
临床医学名词词典
首页 > 按专业查询名词 > 查询PubMed相关文献
名词信息
Pubmed相关的文献
single non drug eluting stent implantation with left main coronary artery disease相关文献:
Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial.
Kirtane AJ, Généreux P, Lewis B, Shlofmitz RA, Dohad S, Choudary J, Dahle T, Pineda AM, Shunk K, Maehara A, Popma A, Redfors B, Ali ZA, Krucoff M, Armstrong E, Kandzari DE, O'Neill W, Kraemer C, Stiefel KM, Jones DE, Chambers J, Stone GW; ECLIPSE Investigators.
Lancet. 2025 Apr 12;405(10486):1240-1251. doi: 10.1016/S0140-6736(25)00450-7. Epub 2025 Mar 30.
PMID:40174596
Bioadaptor implant versus contemporary drug-eluting stent in percutaneous coronary interventions in Sweden (INFINITY-SWEDEHEART): a single-blind, non-inferiority, registry-based, randomised controlled trial.
Erlinge D, Andersson J, Fröbert O, Törnerud M, Hamid M, Kellerth T, Grimfjärd P, Winnberg O, Jurga J, Wagner H, Zwackman S, Adielsson M, Alström P, Masoe E, Ulvenstam A, Millgård J, Böhm F, Held C, Renlund H, Oldgren J, Smits PC, Elek C, Abizaid A, James S.
Lancet. 2024 Nov 2;404(10464):1750-1759. doi: 10.1016/S0140-6736(24)02227-X. Epub 2024 Oct 28.
PMID:39481425
Firesorb bioresorbable scaffold for de novo coronary artery disease: 1-year clinical outcomes.
Jiang J, Li C, Chen D, Song L, Cui Z, Li P, Gan L, Chen Y, Li H, Jia S, He S, Lu W, Gao R, Wang J; FUTURE III Investigators.
BMC Med. 2025 Jul 9;23(1):419. doi: 10.1186/s12916-025-04254-0.
PMID:40629329
[Interventional cardiology].
Albarrán A, Pinar E, Baz JA, Mauri J.
Rev Esp Cardiol. 2008 Feb;61 Suppl 1:72-85.
PMID:18341937
Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease.
Degertekin M, Regar E, Tanabe K, Lee CH, Serruys PW.
Minerva Cardioangiol. 2002 Oct;50(5):405-18.
PMID:12384623
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial.
Piccolo R, Calabrò P, Carrara G, Varricchio A, Baldi C, Napolitano G, De Simone C, Mauro C, Stabile E, Caiazzo G, Tesorio T, Boccalatte M, Tuccillo B, Cirillo P, Di Serafino L, Simonetti F, Leone A, Angellotti D, Bottiglieri G, Russolillo E, Galasso G, Perrotta R, Cesaro A, Niglio T, Capasso M, Spinelli A, Cristiano S, Faretra A, Bruzzese D, Chieffo A, Tarantini G, Leonardi S, Biscaglia S, Costa F, Cassese S, McFadden E, Heg D, Franzone A, Stefanini GG, Capodanno D, Esposito G, Parthenope Investigators FT.
EuroIntervention. 2025 Jan 6;21(1):58-72. doi: 10.4244/EIJ-D-24-00657.
PMID:39773824
Clinical outcomes of sirolimus with eluting stent implantation in coronary artery disease.
Ali M, Shah SM, Shah Z, Hussain I, Syed KS, Khan HM.
J Pak Med Assoc. 2008 Aug;58(8):449-52.
PMID:18822644
Application of the Academic Research Consortium High Bleeding Risk criteria in patients treated with coronary bioresorbable polymer everolimus-eluting stents: Insights from the POEM trial.
Popolo Rubbio A, Testa L, Pivato CA, Regazzoli D, Piccolo R, Esposito G, Musto C, Scalia L, Pacchioni A, Briguori C, Lucisano L, De Luca L, Conrotto F, Tartaglia F, Latini AC, Stankowski K, Chiarito M, Sardella G, Indolfi C, Bedogni F, Reimers B, Condorelli G, Stefanini GG.
Cardiovasc Revasc Med. 2024 Oct;67:77-83. doi: 10.1016/j.carrev.2024.04.022. Epub 2024 Apr 16.
PMID:38702260
Dual antiplatelet therapy after coronary drug-eluting stent implantation in China: A large single center study.
Xu JJ, Gao Z, Zhang Y, Gao LJ, Chen J, Qiao SB, Gao RL, Yang YJ, Xu B, Yuan JQ.
Catheter Cardiovasc Interv. 2018 Feb 15;91(S1):566-572. doi: 10.1002/ccd.27500. Epub 2018 Jan 23.
PMID:29359390
Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease.
Tamburino C, Angiolillo DJ, Capranzano P, Di Salvo M, Ussia G, La Manna A, Guzman LA, Galassi AR, Bass TA.
Catheter Cardiovasc Interv. 2009 Feb 15;73(3):291-8. doi: 10.1002/ccd.21840.
PMID:19214963
© Copyright 2021 鸿泰茂源  版权所有All Rights Reserved京ICP备11040441号-3